Datopotamab deruxtecan (Dato-DXd) is a novel ADC combining the humanized datopotamab antibody targeting TROP2 with the toxic payload DXd, a topoisomerase I inhibitor (i.e., an exatecan derivative), through a cleavable linker that allows for its time-dependent release in the tumor tissue (16). The gene discussed is TACSTD2; the disease is neoplasm.